Prof. Dr. Markus Otto

Institut für Neurologie

Position: Prof. for Neurology (W3) head of the outpatient unit,

               Vice-chair Department of Neurology,

               head of the research laboratory for Neurochemical

               Dementia Diagnostics, Department of Neurology,


Adresse:    Oberer Eselsberg 45

                  89081 Ulm


Tel.:           ++49- 731-500-63010

Fax.:           ++49- 731-500-63012

E-mail:        markus.otto@uni-ulm.de



kurz CV:  

Education:       Study of Medicine (Mainz, London, Zürich); clinical training in Neurology (Göttingen)

Institution and Location  Degree                             Year       Field of Study

Medical School Mainz       dissertation                    1995     Electrophysiolgy, Neurophysiology

University Göttingen         "Facharzt“ for Neurology   2000     Clinical Neurology

University Göttingen        "Habilitation"                   2002    Clinical Neurology

University Göttingen         Intensive care medicine   2003    Clinical Neurology, Intensive care


Scientific training/Positions:

since 2006    Professorship for Neurology at the University of Ulm (W3 – full professor), Vice

                     chairmen of the department of Neurology, head of out-patients department


2005            Professorship for Neuropsychiatry Dementia Research (W2; Department of

                     Neurology and Psychiatry, Göttingen – full professor)


1995-2005    Department of Neurology and Department of Psychiatry, University of Göttingen


1991-1992    Department of Neurobiology, University of Mainz; grant of the University of Mainz


1990-1991    Sobell Department of Neurophysiology (Sears, Kirkwood), National Hospital for

                     Nervous Diseases and Institute of Neurology, London; grant:  "British German

                     Academic Research Collaboration Programme"


Organisation/Management/honors:

since 2011    Elected to speaker board – German competence net neurodeg. dementias

since 2011    Speaker of the German FTLD consortium (www.ftld.de)

since 2011    Scientific advisory board of Neuroallianz

since 2010    Scientific advisory board of the Protein research Unit Ruhr (PURE)

since 2009    Scientific advisory board of the German Competence Network Diabetes

2009-2013    Elected chair - German Society of Neurochemistry and Laboratory diagnosis

since 2005    Executive committee – German Society of Neurochemistry and Laboratory

                    diagnosis

since 2007    Coordinator of interdisplinary research program – Neuroproteomics of Parkinsons

                    dementia funded by State of Baden-Württemberg

2002-2005    responsible for neurochemical core modul center of the German dementia net,

                    Department of Psychiatry, Göttingen

1997-2005    responsible for reference lab for the laboratory diagnosis of spongiform

                    encephalopathies, Göttingen


    

Funding and research areas 1996-2013:

current:


BMBF: Establishment of a network for registration and diagnosis of patients with frontotemporal lobar degeneration / Einrichtung eines Netzwerkes zur zur Erfassung der Diagnostik der frontotemporalen Lobärdegeneration (speaker M. Otto, www.ftld.de)


BMBF: Establishment of a Biomaterialbank for patients with motoneuron diseases / Aufbau einer Biomaterialbank zur Charakterisierung von Motoneuroerkrankungen (M. Otto, subproject of MND net, speaker: Albert Ludolph)


BMBF: Validation of neurochemical markers in multiple sclerosis / Validierung von Neurochemischen Markern bei MS Patienten (Ulm: Tumani, Otto)


EU: Nanosystems for early Diagnosis of Neurodegenerative Diseases (NaDiNe, coordinator: Jörg Kutter, Kopenhagen, Ulm: M. Otto)


EU: Sampling and biomarker OPtimization and Harmonization In ALS and other motor neuron disease (coordinator: Leonard van den Berg, Amsterdam)


EU: Biomarkers for Alzheimer’s disease and Parkinson’s disease (coordinator: Kay Blennow, Gothenborg)


Landesstiftung Baden-Württenberg: Validation of Proteomic markers in patients with parkinsons dementia  (coordinator. M. Otto)


Thierry Latran Foundation: Proteomic approaches for subtyping of ALS patients (coordination: M. Otto; Partner: Olaf Jahn (MPI für experimentelle Medizin Göttingen)


Forschungsverbund BioCenter: Pathophysiological and diagnostic approaches toward Parkinson´s disease and Parkinsons disease dementia; coordinator: M. Otto, Partner: B. Hengerer (Boehringer Ingelheim), K. Danzer (Uni Ulm)


BMWi: Development of Assays for Alzheimer´s disease


Past projects


Landesstiftung Baden-Württenberg (foundation of the state Baden-Wuerttemberg): Proteomische Ansätze zur Früh- und Differentialdiagnose der Parkinson-Demenz Erkrankung – proteomic applications in the early diagnosis of parkinson´s disease (coordinator: M. Otto,  Partner: Bastian Hengerer (Boehringer Ingelheim, Biberach) Michael Przybylski (Uni Konstanz) 


EU: Clinical Neuroproteomics of Neurodegenerative Diseases (cNeupro, coordinator: Jens Wiltfang)


EU: Microfluid total analysis system for the early diagnosis of neurodegenerative disorders (NeuroTAS, coordinator: Jörg Kutter, Kopenhagen)


EU: Development of a pre-clinical blood test for prion diseases (Anteprion, coordinator: Peter Peters, Amsterdam, 06/2006 – 05/2009)


BMBF: Follow-up and therapy study on patients with Creutzfeldt-Jakob disease; coordinator: M. Otto, 2002 - 7/2007)


DFG/CMBP: Proteomanalyse zur Diagnose von Parkinson-Syndromen: Ulm: Otto (Förderung 2005-2006)


BMGS: Labordiagnostische Verfahren zur Früherkennung der transmissiblen spongiformen Enzephalopathien (GZ: 325-4471-02/33); Konsiliarlabor für CJD, M. Otto (1997 - 10/2005)


BMBF: Frühdiagnose transmissibler spongiformer Enzephalopathien durch Proteomanalyse Göttingen: Otto (2002 - 10/2005)


DFG/CMBP: Proteomanalyse bei Neurodegenerativen Erkrankungen: Otto, Wiltfang (2002-2005)


EU: Erasmus mundus program (27926-1C-1-2003-1-FR): planning and organization of European master for tropical neurology (coordinator: Limoges University, Ulm: Otto; 2003 - 2006)


EU: Diagnosis and Function of 14-3-3 Proteins in CJD (1998-2002) (coordinator: Alastair Aitken, Edinburgh; Göttingen: Otto)


VerUm Stiftung: Untersuchung zur pathophysiologisch fundierten klinisch-chemischen Früh- und Differentialdiagnostik dementieller Erkrankungen, Wiltfang, Otto, Poser, Kornhuber (1997-1999)


Asta-Medica: Therapiestudie mit Flupirtin bei Patienten mit Creutzfeldt-Jakob Krankheit Antragsteller: Otto, Poser, Prange (1996 –2002)


Byk-Sangtec: Wertigkeit von S-100 beim Schlaganfall; Wertigkeit der S-100 Bestimmung bei Störung der Blut-Hirn-Schranke: Antragsteller: Otto (1996-1999)


Six publications out of more than 130

Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, Costa J, Cudkowicz M, Glass J, Jahn O, Lehnert S, Malaspina A, Parnetti L, Petzold A, Shaw P, Sherman A, Steinacker P, Süssmuth S, Teunissen C, Tumani H, Wuolikainen A, Ludolph A. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 2012; 13: 1-10.


Lehnert, S., S. Jesse, W. Rist, P. Steinacker, H. Soininen, S. K. Herukka, H. Tumani, M. Lenter, P. Oeckl, B. Ferger, B. Hengerer and M. Otto (2012). "iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia." Exp Neurol 234(2): 499-505.


Steinacker P, Hawlik A, Lehnert S, Jahn O, Meier S, Gorz E, Braunstein KE, Krzovska M, Schwalenstocker B, Jesse S, Propper C, Bockers T, Ludolph A, Otto M. Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis. Am J Pathol 2010a; 176: 1409-20


Steinacker P, Hendrich C, Sperfeld AD, Jesse S, von Arnim CA, Lehnert S, Pabst A, Uttner I, Tumani H, Lee VM, Trojanowski JQ, Kretzschmar HA, Ludolph A, Neumann M, Otto M. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008; 65: 1481-7.


Brechlin P, Jahn O, Steinacher P, Cepek L, Kratzin H, Lehnert S, Jesse S, Mollenhauer B, Kretzschmar H, Wiltfang J, Otto M. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2D-DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob Disease. Proteomics 2008; 8: 4357-4366


Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, Irle E, Pergande G, Ellers-Lenz B, Windl O, Kretzschmar HA, Poser S, Prange H. Efficacy of Flupirtine on Cognitive Function in Patients with CJD: a double blind study. Neurology 2004; 62: 714-8.